Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Fabiana Ciciriello"'
Autor:
Chiara Rosazza, Laura Alagna, Alessandra Bandera, Arianna Biffi, Fabiana Ciciriello, Andrea Gramegna, Vincenzina Lucidi, Paola Giovanna Marchisio, Paola Medino, Antonio Muscatiello, Sara Uceda Renteria, Carla Colombo
Publikováno v:
Italian Journal of Pediatrics, Vol 49, Iss 1, Pp 1-8 (2023)
Abstract Background Children tend to have milder forms of COVID-19 than adults, however post-acute complications have been observed also in the paediatric population. In this study, we compared COVID-19-related outcomes and long-term complications be
Externí odkaz:
https://doaj.org/article/a2f86842a68943d2bcbccef8152277cd
Autor:
Michał Dębczyński, Damian Mojsak, Serena Tamburro, Simona Baldassari, Ilaria Musante, Rosaria Casciaro, Fabiana Ciciriello, Federico Zara, Paolo Scudieri, Giulia Gorrieri
Publikováno v:
Stem Cell Research, Vol 72, Iss , Pp 103232- (2023)
Cystic Fibrosis Transmembrane conductance Regulator (CFTR) is a chloride channel defective in cystic fibrosis (CF). Several CFTR mutations are causative of CF, among which G542X is a nonsense mutation introducing a premature stop codon which prevents
Externí odkaz:
https://doaj.org/article/4a50fda3f923421b9c320b02619a784a
Autor:
Noemi Poerio, Camilla Riva, Tommaso Olimpieri, Marco Rossi, Nicola I. Lorè, Federica De Santis, Lucia Henrici De Angelis, Fabiana Ciciriello, Marco M. D’Andrea, Vincenzina Lucidi, Daniela M. Cirillo, Maurizio Fraziano
Publikováno v:
Microbiology Spectrum, Vol 10, Iss 1 (2022)
ABSTRACT Mycobacterium abscessus is the etiological agent of severe pulmonary infections in vulnerable patients, such as those with cystic fibrosis (CF), where it represents a relevant cause of morbidity and mortality. Treatment of pulmonary infectio
Externí odkaz:
https://doaj.org/article/7726a65d201041f89d078694713c0244
Autor:
Paola Medino, Gianfranco Alicandro, Chiara Rosazza, Fabiana Ciciriello, Andrea Gramegna, Arianna Biffi, Valeria Daccò, Vincenzina Lucidi, Marco Cipolli, Mariaserena Boraso, Erica Nazzari, Carla Colombo
Publikováno v:
Biomedicines, Vol 10, Iss 11, p 2771 (2022)
Background: The impact of COVID-19 on respiratory outcomes in people with cystic fibrosis (pwCF) has not been clearly characterized. We evaluated changes in respiratory function indicators derived from spirometry and pulmonary exacerbation rates 6 mo
Externí odkaz:
https://doaj.org/article/df6600ddbdec4e1bac3711d4ac105076
Autor:
Noemi Poerio, Federica De Santis, Alice Rossi, Serena Ranucci, Ida De Fino, Ana Henriquez, Marco M. D’Andrea, Fabiana Ciciriello, Vincenzina Lucidi, Roberto Nisini, Alessandra Bragonzi, Maurizio Fraziano
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Despite intensive antimicrobial and anti-inflammatory therapies, cystic fibrosis (CF) patients are subjected to chronic infections due to opportunistic pathogens, including multidrug resistant (MDR) Pseudomonas aeruginosa. Macrophages from CF patient
Externí odkaz:
https://doaj.org/article/02a8ed2fc956448eaf6d2a7d63d81e11
Autor:
Paolo Scudieri, Ilaria Musante, Arianna Venturini, Daniela Guidone, Michele Genovese, Federico Cresta, Emanuela Caci, Alessandro Palleschi, Marco Poeta, Francesca Santamaria, Fabiana Ciciriello, Vincenzina Lucidi, Luis J. V. Galietta
Publikováno v:
Cells, Vol 9, Iss 9, p 2090 (2020)
The airway epithelium contains ionocytes, a rare cell type with high expression of Forkhead Box I1 (FOXI1) transcription factor and Cystic Fibrosis Transmembrane conductance Regulator (CFTR), a chloride channel that is defective in cystic fibrosis (C
Externí odkaz:
https://doaj.org/article/ee368ab527914c89a92253aca0659915
Publikováno v:
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
Elexacaftor-tezacaftor-ivacaftor (ETI) represents a significant step forward in cystic fibrosis (CF) care and could change the course of CF lung disease and quality of life for many people with CF (PwCF). However, several PwCF cannot benefit from the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e129d2f3404ff6f2a7556c12ce5e0aab
https://pubmed.ncbi.nlm.nih.gov/36549989
https://pubmed.ncbi.nlm.nih.gov/36549989
Autor:
Matthieu Cornet, Geneviève Robin, Fabiana Ciciriello, Tiphaine Bihouee, Christophe Marguet, Valérie Roy, Muriel Lebourgeois, Frédérique Chedevergne, Anne Sophie Bonnel, Mairead Kelly, Philippe Reix, Vincenzina Lucidi, Véronique Stoven, Isabelle Sermet‐Gaudelus
Publikováno v:
Pediatric pulmonologyREFERENCES. 57(12)
Clinical trials for CFTR modulators consider mean changes of clinical status at the cohort level, and thus fail to assess the heterogeneity of the response. We aimed to study the different response profiles to lumacaftor-ivacaftor according to age in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::225f7dd994c68718258a3da158dbc867
https://pubmed.ncbi.nlm.nih.gov/35996214
https://pubmed.ncbi.nlm.nih.gov/35996214
Autor:
Ramanath Narayana Hegde, Seetharaman Parashuraman, Francesco Iorio, Fabiana Ciciriello, Fabrizio Capuani, Annamaria Carissimo, Diego Carrella, Vincenzo Belcastro, Advait Subramanian, Laura Bounti, Maria Persico, Graeme Carlile, Luis Galietta, David Y Thomas, Diego Di Bernardo, Alberto Luini
Publikováno v:
eLife, Vol 4 (2015)
Cystic fibrosis (CF) is caused by mutations in CF transmembrane conductance regulator (CFTR). The most frequent mutation (F508del-CFTR) results in altered proteostasis, that is, in the misfolding and intracellular degradation of the protein. The F508
Externí odkaz:
https://doaj.org/article/539e56c235594b23a5b171eb590f887b
Autor:
Antonella Tosco, Alice Castaldo, Carla Colombo, Laura Claut, Vincenzo Carnovale, Paola Iacotucci, Marco Lucarelli, Giuseppe Cimino, Benedetta Fabrizzi, Nicole Caporelli, Fabio Majo, Fabiana Ciciriello, Rita Padoan, Piercarlo Poli, Giovanni Taccetti, Claudia Centrone, Rosaria Casciaro, Carlo Castellani, Donatello Salvatore, Carmela Colangelo, Paolo Bonomi, Giuseppe Castaldo, Vito Terlizzi
Publikováno v:
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 21(5)
In recent years, patients with cystic fibrosis (CF) conductance regulator (CFTR) variant poly(T) sequences have been increasingly reported with a wide spectrum of clinical severity. We describe the long-term clinical outcomes and progression to a CF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d55043b344d45131c9c4ba61d15d6cd9
https://pubmed.ncbi.nlm.nih.gov/35523714
https://pubmed.ncbi.nlm.nih.gov/35523714